Treatment-free remission in patients with chronic myeloid leukemia: literature review
Tyrosine kinase inhibitors have radically changed the course of chronic myeloid leukemia, significantly increasing survival and reducing the risk of disease progression. Nearly 50–70 % of patients achieve a consistently low or undetectable level of minimal residual disease – a deep molecular respons...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024626598445056 |
|---|---|
| author | A. N. Petrova E. Yu. Chelysheva A. G. Turkina |
| author_facet | A. N. Petrova E. Yu. Chelysheva A. G. Turkina |
| author_sort | A. N. Petrova |
| collection | DOAJ |
| description | Tyrosine kinase inhibitors have radically changed the course of chronic myeloid leukemia, significantly increasing survival and reducing the risk of disease progression. Nearly 50–70 % of patients achieve a consistently low or undetectable level of minimal residual disease – a deep molecular response. The long-term tyrosine kinase inhibitors treatment in about one-third of patients is accompanied by toxicity which impairs the quality of life. Therefore, the safe treatment discontinuation is relevant. The results of clinical trials have shown 40-60% possibility of maintaining treatment-free remission in patients with long-term deep molecular respons; however, all patients with molecular relapse regain molecular remission after the resumption of tyrosine kinase inhibitors therapy. Currently, clinical and biological factors associated with maintaining treatment-free remission are being studied. It is assumed that cessation of tyrosine kinase inhibitors therapy can improve the quality of life, but approximately 30 % of patients are reporting musculoskeletal pain – so called “withdrawal syndrome” – that begins or worsens after stopping tyrosine kinase inhibitors therapy. The mechanisms for the development of this phenomenon are currently unclear. Thus, many aspects concerning treatment-free remission require to be studied, which determines the importance of clinical trials in this area. |
| format | Article |
| id | doaj-art-ba93ffdb226740f69248cdb796dc8e20 |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2019-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-ba93ffdb226740f69248cdb796dc8e202025-08-20T03:01:03ZrusABV-pressОнкогематология1818-83462413-40232019-10-01143122210.17650/1818-8346-2019-14-3-12-22316Treatment-free remission in patients with chronic myeloid leukemia: literature reviewA. N. Petrova0E. Yu. Chelysheva1A. G. Turkina2National Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaTyrosine kinase inhibitors have radically changed the course of chronic myeloid leukemia, significantly increasing survival and reducing the risk of disease progression. Nearly 50–70 % of patients achieve a consistently low or undetectable level of minimal residual disease – a deep molecular response. The long-term tyrosine kinase inhibitors treatment in about one-third of patients is accompanied by toxicity which impairs the quality of life. Therefore, the safe treatment discontinuation is relevant. The results of clinical trials have shown 40-60% possibility of maintaining treatment-free remission in patients with long-term deep molecular respons; however, all patients with molecular relapse regain molecular remission after the resumption of tyrosine kinase inhibitors therapy. Currently, clinical and biological factors associated with maintaining treatment-free remission are being studied. It is assumed that cessation of tyrosine kinase inhibitors therapy can improve the quality of life, but approximately 30 % of patients are reporting musculoskeletal pain – so called “withdrawal syndrome” – that begins or worsens after stopping tyrosine kinase inhibitors therapy. The mechanisms for the development of this phenomenon are currently unclear. Thus, many aspects concerning treatment-free remission require to be studied, which determines the importance of clinical trials in this area.https://oncohematology.abvpress.ru/ongm/article/view/367chronic myeloid leukemiatyrosine kinase inhibitordeep molecular responsetreatment free remission |
| spellingShingle | A. N. Petrova E. Yu. Chelysheva A. G. Turkina Treatment-free remission in patients with chronic myeloid leukemia: literature review Онкогематология chronic myeloid leukemia tyrosine kinase inhibitor deep molecular response treatment free remission |
| title | Treatment-free remission in patients with chronic myeloid leukemia: literature review |
| title_full | Treatment-free remission in patients with chronic myeloid leukemia: literature review |
| title_fullStr | Treatment-free remission in patients with chronic myeloid leukemia: literature review |
| title_full_unstemmed | Treatment-free remission in patients with chronic myeloid leukemia: literature review |
| title_short | Treatment-free remission in patients with chronic myeloid leukemia: literature review |
| title_sort | treatment free remission in patients with chronic myeloid leukemia literature review |
| topic | chronic myeloid leukemia tyrosine kinase inhibitor deep molecular response treatment free remission |
| url | https://oncohematology.abvpress.ru/ongm/article/view/367 |
| work_keys_str_mv | AT anpetrova treatmentfreeremissioninpatientswithchronicmyeloidleukemialiteraturereview AT eyuchelysheva treatmentfreeremissioninpatientswithchronicmyeloidleukemialiteraturereview AT agturkina treatmentfreeremissioninpatientswithchronicmyeloidleukemialiteraturereview |